Your trusted source for investing success

Tag: ODD

Propanc Provides Shareholder Update and Forecast for 2017

Propanc Health Group Corporation (OTCQB: PPCH),  an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced an update on the significant progress of the Company and its R&D activities in 2016 and

Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG)

NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced topline
results from the REGAIN study, a Phase 3 registration trial of
eculizumab (Soliris®) in patients with refractory generalized
myasthenia gravis (gMG). Refractory gMG is an ultra-rare segment of MG—a
debilitating, complement-mediated neuromuscular disease—in which
patients have largely exhausted conventional therapy and continue to
suffer profound

K-Cup for Marijuana?

A former Keurig VP is launching a single serving pot vaporizer through his new company, CannaKorp, the Boston Globe reported.

As quoted in the publication:
Today, Bourque is the cofounder of CannaKorp Inc., a Stoneham company making a marijuana vaporizer that has an inevitable comparison to the instant coffee machines made by Keurig,

Hemispherx Biopharma Enters into Alfa-n3 Interferon Clinical Trial, Sales, Marketing, Distribution, and Supply Agreement with Saudi Arabia’s Premier Pharma Company in Fight Against the Deadly MERS Disease

PHILADELPHIA, April 19, 2016 (GLOBE NEWSWIRE) — Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the Company) announced today that it has entered into a Clinical Trial, Sales, Marketing, Distribution, and Supply Agreement with Scientific Products Pharmaceutical Co. LTD (SCIEN) located in Riyadh,  Saudi Arabia. The contract covers Saudi Arabia, United Arab Emirates,

Gold Outlook 2017!

Click here to get a clear perspective on the gold price and what the experts see coming in 2017 with our FREE Special Report (value of $49). Limited time offer. No credit card required.   Get My Free Report  
Enter Your Log In Credentials

Privacy & Legal Policy

Privacy Policy

Investing News Network